Merck KGaA retools F-star pact, walks away from lead PD-L1 drug

Merck KGaA has revised the bispecific immuno-oncology antibody agreement it struck with F-star in 2017. The Big Pharma has exercised its option on a discovery program but walked away from phase 1 LAG-3 PD-L1 bispecific FS118.